Skip to main content
    • Aa
    • Aa

Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway

  • William E. Tidyman (a1) and Katherine A. Rauen (a2) (a3)

A class of developmental disorders caused by dysregulation of the Ras-induced mitogen-activated protein kinase (MAPK) cascade (the Ras–MAPK pathway) has emerged. Three of these disorders – Noonan, Costello and cardio–facio–cutaneous syndromes – have overlapping phenotypic features characterised by distinctive facial dysmorphia, cardiac defects, musculoskeletal and cutaneous abnormalities, and neurocognitive delay. The germline mutations associated with these disorders are in genes that encode proteins of the Ras–MAPK pathway. In vitro studies have determined that the overwhelming majority of these mutations result in increased signal transduction down the pathway, but usually to a lesser degree than somatic mutations in the same genes that are associated with cancer. The Ras–MAPK pathway is essential in the regulation of the cell cycle, differentiation, growth and senescence, so it is not surprising that germline mutations that affect its function have profound effects on development. Here we review the clinical consequences of the known molecular lesions associated with Noonan syndrome, Costello syndrome and cardio–facio–cutaneous syndrome, and explore possible therapeutic modalities for treatment.

Corresponding author
*Corresponding author: Katherine A. Rauen, UCSF Helen Diller Family Comprehensive Cancer Center, 2340 Sutter Street, Room S429, Box 0128, San Francisco, CA 94115, USA. Tel: +1 415 514 3513; Fax: +1 415 502 3179; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 J.F. Hancock (2003) Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4, 373-384

3 R.S. Midgley and D.J. Kerr (2002) Ras as a target in cancer therapy. Crit Rev Oncol Hematol 44, 109-120

4 S. Yoon and R. Seger (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44

5 O. Haccard (1995) Induction of Xenopus oocyte meiotic maturation by MAP kinase. Dev Biol 168, 677-682

6 O. Haccard (1993) Induction of metaphase arrest in cleaving Xenopus embryos by MAP kinase. Science 262, 1262-1265

7 O. Haccard (1993) Mitogen-activated protein kinase (MAP kinase) activation in Xenopus oocytes: roles of MPF and protein synthesis. Mol Reprod Dev 36, 96-105

8 K.L. Curran and R.M. Grainger (2000) Expression of activated MAP kinase in Xenopus laevis embryos: evaluating the roles of FGF and other signaling pathways in early induction and patterning. Dev Biol 228, 41-56

10 Y. Gotoh and E. Nishida (1995) Activation mechanism and function of the MAP kinase cascade. Mol Reprod Dev 42, 486-492

12 M. Furthauer (2004) Fgf signalling controls the dorsoventral patterning of the zebrafish embryo. Development 131, 2853-2864

13 L.B. Corson (2003) Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130, 4527-4537

14 L.G. Leichtman (1996) Are cardio-facio-cutaneous syndrome and Noonan syndrome distinct? A case of CFC offspring of a mother with Noonan syndrome. Clin Dysmorphol 5, 61-64

15 A.E. Fryer , P.J. Holt and H.E. Hughes (1991) The cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome: are they the same? Am J Med Genet 38, 548-551

16 G. Neri and M. Zollino (1996) More on the Noonan-CFC controversy [editorial; comment]. Am J Med Genet 65, 100

17 G. Neri and J.M. Opitz (2000) Heterogeneity of cardio-facio-cutaneous syndrome. Am J Med Genet 95, 144

18 M. Tartaglia (2003) Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes. Clin Genet 63, 423-426

19 J.A. Noonan (1968) Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116, 373-380

20 A.C. Shaw (2007) The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 92, 128-132

21 A.E. Lin (1988) Noonan syndrome. J Med Genet 25, 64-65

22 D.J. Reynolds (2004) Ocular manifestations of Noonan syndrome in the pediatric patient. J AAPOS 8, 282-283

23 A.A. Massarano (1996) Noonan syndrome: coagulation and clinical aspects. Acta Paediatr 85, 1181-1185

24 D.A. Lee (2005) Psychological profile of children with Noonan syndrome. Dev Med Child Neurol 47, 35-38

25 M. Holder-Espinasse and R.M. Winter (2003) Type 1 Arnold-Chiari malformation and Noonan syndrome. A new diagnostic feature? Clin Dysmorphol 12, 275

26 K. Choong (1999) Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 21, 523-527

27 S.P. Attard-Montalto , J.E. Kingston and T. Eden (1994) “Noonan's syndrome and acute lymphoblastic leukaemia”. Med Pediatr Oncol 23, 391-392

28 B. Bader-Meunier (1997) Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130, 885-889

29 M. Moschovi (2007) Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J Pediatr Hematol Oncol 29, 341-344

30 G. Roti (2006) Acute lymphoblastic leukaemia in Noonan syndrome. Br J Haematol 133, 448-450

31 M. Piombo (1993) Acute lymphoblastic leukemia in Noonan syndrome: report of two cases. Med Pediatr Oncol 21, 454-455

32 M. Tartaglia (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29, 465-468

33 A.E. Roberts (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39, 70-74

34 M. Tartaglia (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39, 75-79

35 B. Pandit (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39, 1007-1012

36 M.A. Razzaque (2007) Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39, 1013-1017

37 S. Schubbert (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38, 331-336

38 M. Zenker (2007) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44, 131-135

39 M. Tartaglia (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70, 1555-1563

40 P. Hof (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450

41 H. Keilhack (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280, 30984-30993

42 M. Tartaglia (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78, 279-290

43 A. Fragale (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23, 267-277

44 T. Niihori (2005) Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 50, 192-202

45 T. Araki (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10, 849-857

46 A.M. O'Reilly (2000) Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol 20, 299-311

47 S. Martinelli (2008) Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 17, 2018-2029

48 C.P. Kratz (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106, 2183-2185

49 M. Tartaglia (2004) Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104, 307-313

50 M. Bentires-Alj (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64, 8816-8820

51 Y. Chen (2006) Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 45, 583-591

52 M.L. Loh (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103, 2325-2331

53 D. Miyamoto (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27, 3508-3515

54 S. Schubbert (2005) Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106, 311-317

55 R. Yoshida (2008) Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. Pediatr Blood Cancer 50, 1274-1276

56 M. Tartaglia (2004) Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. Am J Hum Genet 75, 492-497

58 T. Niihori (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38, 294-296

59 S. Schubbert (2007) Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27, 7765-7770

60 C. Carta (2006) Germline missense mutations affecting KRAS isoform B are associated with a severe noonan syndrome phenotype. Am J Hum Genet 79, 129-135

61 M. Zenker (2007) SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44, 651-656

62 K.D. Swanson (2008) SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer 47, 253-259

63 V. Emuss (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65, 9719-9726

67 K.A. Rauen (2007) HRAS and the Costello syndrome. Clin Genet 71, 101-108

68 W.K. Yassir , B.E. Grottkau and M.J. Goldberg (2003) Costello syndrome: orthopaedic manifestations and functional health. J Pediatr Orthop 23, 94-98

69 A.E. Lin (2002) Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 111, 115-129

70 M.E. Axelrad (2007) Longitudinal assessment of cognitive characteristics in Costello syndrome. Am J Med Genet A 143A, 3185-3193

78 T. Gordon (2001) Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. Med Pediatr Oncol 36, 259-267

79 A. Tobar (2000) Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma. Diagn Mol Pathol 9, 9-13

80 K.W. Gripp (2002) Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 108, 80-87

81 Y. Aoki (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37, 1038-1040

83 B. Kerr (2006) Genotype-phenotype correlation in Costello syndrome; HRAS mutation analysis in 43 cases. J Med Genet 43, 401-405

84 I.F. Lo (2008) Severe neonatal manifestations of Costello syndrome. J Med Genet 45, 167-171

85 A.L. Schulz (2008) Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet 73, 62-70

86 I. van der Burgt (2007) Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. J Med Genet 44, 459-462

87 M.A. van Steensel (2006) Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 15, 731-734

88 G. Zampino (2007) Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 28, 265-272

89 E. Denayer (2008) Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29, 232-239

90 K.W. Gripp (2008) Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A 146A, 683-690

92 B. Kerr (2008) The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders. Am J Med Genet 146A, 1218-1220

93 K. Sol-Church (2006) Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 27, 736-741

95 J.B. Gibbs (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A 81, 5704-5708

96 J.P. McGrath (1984) Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310, 644-649

97 R.W. Sweet (1984) The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273-275

98 P.H. Seeburg (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312, 71-75

99 O. Fasano (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci U S A 81, 4008-4012

100 R.F. Newbold and R.W. Overell (1983) Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651

101 H. Land , L.F. Parada and R.A. Weinberg (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602

103 P. Levesque (1993) Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer 55, 785-790

104 Y. Takahashi (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17, 660-669

105 J. Yoo and R.A. Robinson (1999) H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer 86, 58-63

106 B. Kerr (2003) Is the locus for Costello syndrome on 11p? J Med Genet 40, 469-471

108 J.F. Reynolds (1986) New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement–the CFC syndrome. Am J Med Genet 25, 413-427

109 L. Borradori and C. Blanchet-Bardon (1993) Skin manifestations of cardio-facio-cutaneous syndrome. J Am Acad Dermatol 28, 815-819

110 G. Weiss (2004) Cutaneous manifestations in the cardiofaciocutaneous syndrome, a variant of the classical Noonan syndrome. Report of a case and review of the literature. J Eur Acad Dermatol Venereol 18, 324-327

111 D. Wieczorek , F. Majewski and G. Gillessen-Kaesbach (1997) Cardio-facio-cutaneous (CFC) syndrome–a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Clin Genet 52, 37-46

113 T.A. Grebe and C. Clericuzio (2000) Neurologic and gastrointestinal dysfunction in cardio-facio-cutaneous syndrome: identification of a severe phenotype. Am J Med Genet 95, 135-143

114 G. Sabatino (1997) The cardio-facio-cutaneous syndrome: a long-term follow-up of two patients, with special reference to the neurological features. Childs Nerv Syst 13, 238-241

115 T.E. Herman and W.H. McAlister (2005) Gastrointestinal and renal abnormalities in cardio-facio-cutaneous syndrome. Pediatr Radiol 35, 202-205

116 P.C. Chan , H.C. Chiu and W.L. Hwu (2002) Spontaneous chylothorax in a case of cardio-facio-cutaneous syndrome. Clin Dysmorphol 11, 297-298

117 G. Yoon (2007) Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol 49, 894-899

118 H. Van Den Berg , R.C.M. Hennekam (1999) Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. J Med Genet 36, 799-800

119 Y. Makita (2007) Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. J Pediatr Hematol Oncol 29, 287-290

121 P. Rodriguez-Viciana (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290

122 C. Wellbrock , M. Karasarides and R. Marais (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5, 875-885

124 C. Nava (2007) Cardio-facio-cutaneous and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome. J Med Genet 44, 763-771

125 K.W. Gripp (2007) Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A 143A, 1472-1480

126 P.T. Wan (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867

127 M.J. Garnett (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20, 963-969

128 H. Davies (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954

130 H. Rajagopalan (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934

131 P.M. Pollock (2003) High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20

132 G. Pearson (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22, 153-183

133 J. Wu (1993) Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. Mol Cell Biol 13, 4539-4548

136 S. Cowley (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852

137 S.J. Mansour (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970

138 V.S. Sivaraman (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99, 1478-1483

139 R. Hoshino (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822

140 G. Bignell (2006) Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45, 42-46

142 C. Hunter (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66, 3987-3991

143 P. Stephens (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37, 590-592

144 A.L. Estep (2007) Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy. PLoS ONE 2, e1279

145 T. Nakamura (2007) Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117, 2123-2132

147 K. Mercer (2005) Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65, 11493-11500

148 L. Wojnowski (2000) Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev 91, 97-104

149 G. Galabova-Kovacs (2006) Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci U S A 103, 1325-1330

150 S. Giroux (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9, 369-372

151 L.F. Belanger (2003) Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23, 4778-4787

152 F.A. Scholl (2007) Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell 12, 615-629

153 J.S. Sebolt-Leopold and R. Herrera (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4, 937-947

154 J.S. Sebolt-Leopold (2008) Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14, 3651-3656

155 J. Tsai (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105, 3041-3046

156 T. Senawong (2008) Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet 17, 419-430

157 D.B. Solit (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362

158 M.C. Digilio (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71, 389-394

159 T.C. Hart (2002) A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am J Hum Genet 70, 943-954

160 I. Eerola (2003) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73, 1240-1249

161 R.M. Cawthon (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193-201

162 D. Viskochil (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192

163 M.R. Wallace (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181-186

164 H. Brems (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39, 1120-1126

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 26
Total number of PDF views: 53 *
Loading metrics...

Abstract views

Total abstract views: 344 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th June 2017. This data will be updated every 24 hours.